STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Constantia Pantelidou(Harvard University), Geoffrey I. Shapiro(Brigham and Women's Hospital)
Cited by 33
Related Papers
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
|Cell|2021|586
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
|Cancer Cell|2006|451
Institutional implementation of clinical tumor profiling on an unselected cancer population
|JCI Insight|2016|447
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
|Cancer Discovery|2017|418
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
|Nature Medicine|2020|393